Arkadios Wealth Advisors Increases Holdings in Zoetis Inc. $ZTS

by · The Cerbat Gem

Arkadios Wealth Advisors grew its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 8.2% during the 2nd quarter, Holdings Channel.com reports. The fund owned 11,978 shares of the company’s stock after acquiring an additional 903 shares during the period. Arkadios Wealth Advisors’ holdings in Zoetis were worth $1,868,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Nova Wealth Management Inc. purchased a new position in shares of Zoetis in the first quarter valued at about $25,000. 1248 Management LLC purchased a new position in shares of Zoetis in the first quarter valued at about $27,000. Saudi Central Bank purchased a new position in shares of Zoetis in the first quarter valued at about $29,000. Cornerstone Planning Group LLC lifted its position in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after acquiring an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC lifted its position in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.1%

Shares of NYSE ZTS opened at $144.25 on Friday. The business’s 50 day moving average is $147.15 and its two-hundred day moving average is $153.36. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $183.11. The stock has a market capitalization of $63.93 billion, a P/E ratio of 24.83, a PEG ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same period in the previous year, the firm posted $1.56 earnings per share. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is presently 34.42%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ZTS shares. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Argus reaffirmed a “buy” rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. UBS Group reduced their target price on Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a report on Monday, October 20th. Finally, Piper Sandler lifted their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $195.00.

View Our Latest Analysis on Zoetis

Zoetis Company Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).